Finding Safe, Effective Ways to Use CAR T Cells Against Solid Cancers

AffyImmune is a clinical stage biotechnology company focused on developing technologies that expand the utility and improve the safety of cell-based immunotherapy for cancer.

AffyImmune’s core focus is on developing CAR T cells effective in treating solid tumors, which account for over 90% of all cancer fatalities. Our Phase I clinical trial of our lead compound in patients with anaplastic or refractory thyroid cancer is now enrolling patients (NCT04420754).


Scientific Advisory Board


AffyImmune Therapeutics is actively seeking partnerships to advance both its pipeline of products and technology development initiatives. If you are interested in partnering with us, please contact us